Haemoglobin and albumin as markers of HIV disease progression in the highly active antiretrovial therapy era: Relationships with gender

HIV Medicine

Volumn 8, Issue 1, 2007, Pages 38-45

  Shah, Sapna ^a   Smith, C J ^a   Lampe, F ^a   Youle, M ^a   Johnson, M A ^a   Phillips, A N ^a   Sabin, C A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Albumin; Disease progression; Gender; Haemoglobin; Highly active antiretroviral therapy

Indexed keywords

ALBUMIN; ANTIRETROVIRUS AGENT; HEMOGLOBIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ALBUMIN BLOOD LEVEL; ANEMIA; ARTICLE; CD4 LYMPHOCYTE COUNT; DEATH; DISEASE COURSE; DISEASE MARKER; FEMALE; HEMOGLOBIN BLOOD LEVEL; HEMOGLOBIN DETERMINATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOALBUMINEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; SEX DIFFERENCE;

ADULT; ANEMIA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; DISEASE PROGRESSION; FEMALE; HEMOGLOBINS; HIV INFECTIONS; HIV-1; HUMANS; HYPOALBUMINEMIA; LONDON; MALE; PROGNOSIS; RISK FACTORS; SERUM ALBUMIN; SEX FACTORS;

EID: 33846299940     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2007.00434.x     Document Type: Article

References (28)

1. Anastos K, Kalish LA, Hessol N et al. The relative value of CD4 cell count and quantitative HIV-1 RNA in predicting survival in HIV-1infected women: Results from the women's interagency HIV study. AIDS 1999; 13: 1717-1726.
2. Kim S, Hughes MD, Hammer SM, Jackson JB, DeGruttola V, Katzenstein DA. Both serum HIV type 1 RNA levels and CD4+ lymphocyte counts predict clinical outcome in HIV type 1-infected subjects with 200-500 CD4+ cells per cubic millimetre. AIDS Res Hum Retroviruses 2000; 16: 645-653.
3. Sabin CA, Griffioen A, Yee TT et al. Markers of HIV-1 diesease progression in individuals with haemophilia coinfected with hepatitis C virus: A longitudinal study. Lancet 2002; 360: 1546-1551.
4. Mekonnen Y, Dukers NH, Sanders E et al. Simple markers for initiating antiretroviral therapy among HIV-infected Ethiopians. AIDS 2003; 17: 815-819.
5. Mofenson LM, Harris DR, Moye J et al. Alternatives to HIV-1 RNA concentration and CD4 count to predict mortality in HIV-1-infected children in resource poor settings. Lancet 2003; 362: 1625-1627.
6. Mocroft A, Bofill M, Lipman M et al. CD8+, CD38+ lymphocyte percent: A useful immunological marker for monitoring HIV-1-infected patients. J Acquir Immune Defic Syndr Hum Retrovirol 1997; 14: 158-162.
7. Moyle G. Anaemia in persons with HIV infection: Prognostic marker a contributor to morbidity. AIDS Rev 2002; 4: 13-20.
8. Moore RD, Keruly JC, Chaisson RE. Anaemia and survival in HIV infection. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19: 29-33.
9. Moore RD, Forney D. Anaemia in HIV-infected patients receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2002; 29: 54-57.
10. Semba RD, Shah N, Vlahov D. Improvement of anaemia among HIV-infected drug users receiving highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26: 315-319.
11. Semba RD, Shah N, Klein RS et al. Highly active antiretroviral therapy associated with improved anaemia among HIV-infected women. AIDS Patient Care STDs 2001; 15: 473-480.
12. Mocroft A, Kirk O, Barton SE et al. Anaemia is an independent predictive marker for clinical prognosis in HIV-infected patients from across Europe. AIDS 1999; 13: 943-950.
13. Lundgren JD, Mocroft A. Anaemia and survival in human immunodeficiency virus. Clin Infect Dis 2003; 37(Suppl. 4): S297-S303.
14. Lundgren JD, Mocroft A, Gatell JM et al. A clinical prognostic scoring system for patients receiving highly active antiretroviral therapy: results from the EuroSIDA study. J Infect Dis 2002; 185: 178-187.
15. Volberding P. The impact of anaemia on quality of life in human immunodeficiency virus-infected patients. J Infect Dis 2002; 185(Suppl. 2): S110-S114.
16. Belperio PS, Rhew DC. Prevalence and outcomes of anaemia in individuals with human immunodeficiency virus: A systematic review of the literature. Am J Med 2004; 116: 27S-43S.
17. Sullivan PS, Hanson DL, Chu SY, Jones JL, Ward JW. Epidemiology of anaemia in human immunodeficiency virus (HIV)-infected persons. Results from the multistate adult and adolescent spectrum of HIV disease surveillance project. Blood 1998; 91: 301-308.
18. Berhane K, Karim R, Cohen MH et al. Impact of highly active antiretroviral therapy on anaemia and relationship between anaemia and survival in a large cohort of HIV-infected women. Women's Interagency HIV Study. J Acquir Immune Defic Syndr 2004; 37: 1245-1252.
19. Obialo CI, Okonofua EC, Nzerue MC, Tayade AS, Riley LJ. Role of hypoalbuminemia and hypocholesterolemia as copredictors of mortality in acute renal failure. Kidney Int 1999; 56: 1058-1063.
20. Miller JE, Russell LB, Davis DM, Milan E, Carson JL, Taylor WC. Biomedical risk factors for hospital admission in older adults. Med Care 1998; 36: 411-421.
21. Feldman JG, Burns DN, Gange SJ et al. Serum albumin as a predictor of survival in HIV-infected women in the Women's Interagency HIV study. AIDS 2000; 14: 863-870.
22. WHO/UNICEF/UNU Iron Deficiency Anaemia. Assessment, Prevention, and Control. A Guide for Programme Managers. WHO/NDH/01.3 Geneva, Switzerland: World Health Organization, 2001.
23. Sabin CA, Lampe FC, Chaloner C et al. An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: The limitations of observational databases when auditing antiretroviral treatment use. HIV Med 2003; 4: 87-93.
24. Whitehead TP, Robinson D, Hale AC, Bailey AR. Clinical Chemistry and Haematology: Adult Reference Values. London, UK: BUPA Medical Research and Development Ltd, 1994.
25. Feldman JG, Gange SJ, Bacchetti P et al. Serum albumin is a powerful predictor of survival among HIV-1 infected women. J Acquir Immune Defic Syndr 2003; 33: 66-73.
26. Weber R, Sabin C, Friis-Moller N et al. Exposure of antiretroviral therapy and the risk of liver-related death: Is there an association? Results from the D:A:D study. 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO, February 2006 [Poster 770].
27. Sanne I, Mommeja-Marin H, Hinkle J et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191: 825-829.
28. Taylor GP, Low-Beer N. Antiretroviral therapy in pregnancy: A focus on safety. Drug Safety 2001; 24: 683-702.